Evommune, Inc., a Delaware corporation incorporated in April 2020, is headquartered in Palo Alto, California. The company is a clinical-stage biotechnology company focused on the development of innovative treatments for the main pathogenic factors of chronic inflammatory diseases. Its initial clinical development projects focus on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis.
